NEW CASTLE, Del., Oct. 18, 2012 (GLOBE NEWSWIRE) -- ScripsAmerica Inc. (OTCBB:SCRC), a leading supplier of prescription, OTC and nutraceutical drugs, today announced the release of a research report by Ludlow Research, a New York based equity research firm. The report can be viewed here.
The research report sets a target price for ScripsAmerica's stock between $1.00 and $1.25 per share, highlighting several factors for the valuation. Among these factors are a US healthcare mandate for cheaper generic drugs, the $25 million US Government contract secured by Marlex Pharmaceuticals, which ScripsAmerica has signed a Letter of Intent to acquire, the upcoming launch of ScripsAmerica's RapiMed product line of children's pain relievers and the Company's potential as a buyout target in the future.
"This research report reflects ScripsAmerica's significant potential for growth, particularly over the next 3 to 6 months, due to conditions in the US health care industry, our upcoming RapiMed launch and the pending completion of our acquisition of Marlex Pharmaceuticals. We are very pleased with the target valuation of our stock put forth in this report over the coming quarters and believe that the Company will achieve and potentially surpass this level of shareholder value," commented Bob Schneiderman CEO of ScripsAmerica.
About Ludlow Equity Research
Ludlow Equity Research assists its clients in generating greater investor and market exposure by providing research and analyst coverage, investor and shareholder relations, and introductions to institutional investors in New York's Financial District for possible capital formation. The company's client services include Equity Research Coverage, Investor and Media Relations, Investor Road Shows, Public Conference Calls and Social Media and Mobile Development. For more information, visit www.ludlowresearch.com.
About ScripsAmerica, Inc.
ScripsAmerica, Inc. delivers pharmaceutical products to a wide range of end users across the health care industry through the largest pharmaceutical distributor in North America, McKesson Corporation. End users include retail pharmacies, hospitals, long-term care facilities and government and home care agencies. Current therapeutic categories serviced by the Company include pain, arthritis, prenatal, urinary, and hormonal replacement drugs. Other customers of ScripsAmerica include Cardinal Health, CutisPharma, Inc., MedVet and the United States Veterans Administration.
For more information, visit www.ScripsAmerica.com.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: 888-959-7095Source:ScripsAmerica, Inc.